Reckitt Benckiser ‘may shelve plan to sell infant-nutrition unit’
infant formula on sale in Alameda, California, 13 October 2020. Owned by Reckitt Benckiser” loading=”lazy” sizes=”(max-width: 1407px) 1407px, (max-width: 335px) 335px, (max-width: 705px) 705px, (max-width: 335px) 335px, (max-width: 689px) 689px, (max-width: 336px) 336px, (max-width: 210px) 210px, (max-width: 101px) 101px, (max-width: 1024px) 1024px, (max-width: 101px) 101px, (max-width: 397px) 397px, (max-width: 464px) 464px, (max-width: 797px) 797px, (max-width: 960px) 960px, (max-width: 314px) 314px, (max-width: 464px) 464px, (max-width: 735px) 735px, (max-width: 1038px) 1038px”/
UK consumer goods major Reckitt Benckiser is reportedly considering postponing plans to sell its infant-formula unit.
News agency Bloomberg, quoting unnamed sources familiar with the situation, said the sale, reputedly worth US$7bn, has fallen victim to “chaos in the industry and worsening financing markets”.
The company reportedly kicked off plans to sell its remaining businesses in infant formula in April and was said to be working with advisers on moves to sell the assets, which include the Enfamil brand. A
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/tronc/WZGIWSRHQNAZ5B7LAEQTNUHSSI.JPG)